[go: up one dir, main page]

Dienstag et al., 1982 - Google Patents

Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen

Dienstag et al., 1982

Document ID
17666354050109369547
Author
Dienstag J
STEVENS C
BHAN A
SZMUNESS W
Publication year
Publication venue
Annals of Internal Medicine

External Links

Snippet

We administered up to 6 monthly doses of hepatitis B vaccine to 16 chronic carriers of hepatitis B surface antigen (HBsAg) in an attempt to eliminate the antigen. The HBsAg in this vaccine differs from native antigen. No patient had elimination of HBsAg, but one of 10 no …
Continue reading at www.acpjournals.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from micro-organisms
    • Y10S530/826—Viruses

Similar Documents

Publication Publication Date Title
Dienstag et al. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen
Zajac et al. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA
Iwarson et al. Protection against hepatitis B virus infection by immunization with hepatitis B core antigen
Ilan et al. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor
Stevens et al. Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization
Maupas et al. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children: controlled trial in an endemic area (Senegal)
Krugman The newly licensed hepatitis B vaccine: Characteristics and indications for use
Barin et al. Immune response in neonates to hepatitis B vaccine
Maupas et al. Hepatitis B vaccine: efficacy in high-risk settings, a two-year study
Soulie et al. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens
Zanetti et al. Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti‐LAV/HTLV‐III‐positive patients
El-Reshaid et al. Comparison of two immunization schedules with recombinant hepatitis B
Byars et al. Improvement of hepatitis B vaccine by the use of a new adjuvant
Weitberg et al. Immunogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy.
Maupas et al. Vaccine against hepatitis B—18 months prevention in a high risk setting
Lelie et al. Immune Response to a Heat-Inactivated Hepatitis B Vaccine in Patients Undergoing Hemodialysis: Enhancement of the Response by Increasing the Dose of Hepatitis B Surface Antigen From 3 to 27 µg
Stephan et al. Modulation of hepatitis B infection by intravenous application of an immunoglobulin preparation that contains antibodies to hepatitis B e and core antigens but not to hepatitis B surface antigen
Callis et al. Hepatitis B virus infection and vaccination in children undergoing hemodialysis
Wiedermann et al. Multicentre dose range study of a yeast-derived hepatitis B vaccine
Anderson et al. Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B.
Francis Selective primary health care: strategies for control of disease in the developing world. III. Hepatitis B virus and its related diseases
Gazengel et al. Use of HBV vaccine in hemophiliacs
SMIT‐LEIJS et al. Hepatitis B vaccination of haemodialysis patients: randomized controlled trial comparing plasma‐derived vaccine with and without pre‐S2 antigen
Thomas et al. Viruses and immune reactions in the liver
Tada et al. Prevention of perinatal transmission of hepatitis B virus carrier state